HIV coinfection with hepatitis b: Difference between revisions
| Line 11: | Line 11: | ||
==Natural History== | ==Natural History== | ||
The rate of progression and complications from viral hepatitis are accelerated in patients with HIV co infection. | The rate of progression and complications from viral hepatitis are accelerated in patients with HIV co infection.<ref name="pmid16964824">{{cite journal |author=Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, Monforte A |title=Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis |journal=Antivir. Ther. (Lond.) |volume=11 |issue=5 |pages=567–74 |year=2006 |pmid=16964824 |doi= |url= |accessdate=2012-03-29}}</ref> | ||
==Reference== | ==Reference== | ||
Revision as of 16:11, 29 March 2012
|
Hepatitis B |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV coinfection with hepatitis b On the Web |
|
American Roentgen Ray Society Images of HIV coinfection with hepatitis b |
|
Risk calculators and risk factors for HIV coinfection with hepatitis b |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Ujjwal Rastogi, MBBS [2]
Overview
Co infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) is common due to shared routes of transmission.
Epidemiology
In areas of low endemicity, such as North America, Australia and Europe, HBV and HIV infection are usually acquired in adulthood through sexual or percutaneous transmission. In areas of low endemicity, the prevalence of chronic co infection is around 5-7% among HIV-infected individuals.[1] In countries with intermediate and high HBV endemicity, the main routes of transmission of HBV are perinatal or in early childhood; in these countries HBV co infection rates are 10-20%.[2] [3][4]
Natural History
The rate of progression and complications from viral hepatitis are accelerated in patients with HIV co infection.[5]
Reference
- ↑ Alter MJ (2006). "Epidemiology of viral hepatitis and HIV co-infection". J. Hepatol. 44 (1 Suppl): S6–9. doi:10.1016/j.jhep.2005.11.004. PMID 16352363. Retrieved 2012-03-29.
- ↑ Lee HC, Ko NY, Lee NY, Chang CM, Ko WC (2008). "Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000-2005: upsurge in hepatitis C virus infections among injection drug users". J. Formos. Med. Assoc. 107 (5): 404–11. doi:10.1016/S0929-6646(08)60106-0. PMID 18492625. Retrieved 2012-03-29. Unknown parameter
|month=ignored (help) - ↑ Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C, Beeching NJ, Zijlstra EE (2008). "Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi". J. Infect. 57 (1): 72–7. doi:10.1016/j.jinf.2008.05.004. PMID 18555534. Retrieved 2012-03-29. Unknown parameter
|month=ignored (help) - ↑ Diop-Ndiaye H, Touré-Kane C, Etard JF, Lô G, Diaw P, Ngom-Gueye NF, Gueye PM, Ba-Fall K, Ndiaye I, Sow PS, Delaporte E, Mboup S (2008). "Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study)". J. Med. Virol. 80 (8): 1332–6. doi:10.1002/jmv.21236. PMID 18551596. Retrieved 2012-03-29. Unknown parameter
|month=ignored (help) - ↑ Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, Monforte A (2006). "Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis". Antivir. Ther. (Lond.). 11 (5): 567–74. PMID 16964824.
|access-date=requires|url=(help)